Efficacy and Safety of Ribavirin plus High Dose Interferonα-2b for Treatment of Patients with Chronic Hepatitis C Who Relapsed After Previous Interferon-α Therapy
碩士 === 國立成功大學 === 臨床藥學研究所 === 89 === Background:The hepatitis C is a major health care problem worldwide. Approximately 85﹪of patients with acute hepatitis C virus( HCV ) infection develop chronic hepatitis and 20-30﹪of these patients will progress to cirrhosis within 10-20 years after infection. Th...
Main Authors: | Hsin-Yi Wang, 王心怡 |
---|---|
Other Authors: | Ting-Tsung Chang |
Format: | Others |
Language: | zh-TW |
Published: |
2001
|
Online Access: | http://ndltd.ncl.edu.tw/handle/30770063425393639237 |
Similar Items
-
Efficacy and safety of triple therapy with recombinant interleukin-1β, recombinant interferon-α and ribavirin in patients with chronic hepatitis C, genotype 1 infection, the non-responders to previous treatment with interferon and ribavirin
by: Yu. V. Lobzin, et al.
Published: (2014-09-01) -
Peginterferon alfa-2a (40KD) (PEGASYS®) plus ribavirin (COPEGUS®) in retreatment of chronic hepatitis C patients, nonresponders and relapsers to previous conventional interferon plus ribavirin therapy
by: E. Parise, et al. -
Efficacy and safety of interferon plus ribavirin in elderly patients with chronic hepatitis C: report of 4 cases
by: CAI Shaoping
Published: (2014-01-01) -
Effects of Host and virus related factors on Interferon-α+ribavirin and Pegylated-interferon+ribavirin treatment outcomes in Chronic Hepatitis C patients
by: Saleem Sana, et al.
Published: (2011-05-01) -
Retreatment of hepatitis C patients with pegylated interferon combined with ribavirin in non-responders to interferon plus ribavirin. Is it different in real life?
by: Gonçales Neiva SL, et al.
Published: (2010-07-01)